The Impact of Angiotensin System Inhibitors on Outcomes in Patients with mRCC
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, discusses a trial that analyzed overall survival in patients with metastatic renal cell carcinoma who used angiotensin system inhibitors.
Clinical Pearls
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, Boston, Massachusetts, discusses a trial that analyzed overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who used angiotensin system inhibitors (ASI).Read more about this trial > >
- This study evaluated OS in ASI users versus nonusers in patients with mRCC
- OS was 27 months compared to 17 months (ASI users vs nonusers, respectively; hazard ratio=1.2)
- In a subset analysis stratified by types of therapy for mRCC (including VEGF-targeted therapy, mTOR-targeted therapy, and IFN-α therapy), the only statistically significant OS benefit was seen in patients receiving VEGF-targeted therapy
<<<
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
